Fri, January 13, 2012
Thu, January 12, 2012
Wed, January 11, 2012
Tue, January 10, 2012
Mon, January 9, 2012
Sun, January 8, 2012
Sat, January 7, 2012
Fri, January 6, 2012
Thu, January 5, 2012
Wed, January 4, 2012
Tue, January 3, 2012
Mon, January 2, 2012
Sat, December 31, 2011
Fri, December 30, 2011
Thu, December 29, 2011
Wed, December 28, 2011

Harwood Feffer LLP Announces Investigation of Pain Therapeutics, Inc.


  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. nces-investigation-of-pain-therapeutics-inc.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

NEW YORK--([ ])--Harwood Feffer LLP ([ www.hfesq.com ]) is investigating potential claims against the board of directors of Pain Therapeutics, Inc. (aPain Therapeuticsa or the aCompanya) (NASDAQ: PTIE), concerning the Companyas failure to comply with U.S. Food and Drug Administration (aFDAa) regulations in the manufacture and testing of a new drug.

On June 24, 2011, Pain Therapeutics announced that the Company had received a Complete Response Letter from the FDA denying the Companyas New Drug Application (aNDAa) for REMOXY. In response, Company stock declined $3.94 per share or nearly 43%, to close at $5.30 per share on June 24, 2011.

On June 27, 2011, the Company disclosed that the FDAas Complete Response Letter raised concerns related to, among other things, the chemistry, manufacturing and controls sections of the NDA for REMOXY. In response, the Company stock declined an additional $1.37 per share or nearly 26%, to close at $3.93 per share on June 27, 2011.

The Company may have improperly failed to disclose that REMOXY was not approvable by the FDA due to chemistry, manufacturing, and control deficiencies that caused unreliable results during laboratory tests.

Our investigation concerns whether the board of directors has breached its fiduciary duties, mismanaged the Company and/or wasted corporate assets at the expense of Pain Therapeutics shareholders.

If you own Pain Therapeutics shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Robert I. Harwood, Esq.
Benjamin Sachs-Michaels
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400

Email: [ bsachsmichaels@hfesq.com ]

Website: [ http://www.hfesq.com ]

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website ([ http://www.hfesq.com ]) for more information about the firm.

Attorney Advertising. 2012 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP ([ www.hfesq.com ]). Prior results do not guarantee or predict a similar outcome with respect to any future matter.


Publication Contributing Sources